Israeli medical device company BrainsWay earned a positive coverage policy from Cigna for its deep transcranial magnetic stimulation to treat adult patients with OCD. Cigna joins the ranks of other major insurers who cover the device for OCD treatment — including Centene, Highmark, Blue Cross Blue Shield, Tricare and Palmetto GBA.
Earlier this year the FDA launched an innovation challenge to help promote and speed-up the development of devices and therapies intended to prevent and treat opioid use disorder.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
An Israeli public company hopes to free patients of multiple drugs that don't relieve major depression by offering a device approach to manage their condition.
The Israeli startup is helping jolt patients out of depression - commercializing a device stateside that harnesses MRI technology to stimulate deep brain tissue to improve mental illness.